Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
RESEARCH TOOLSreports
Holding VVOS?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.4Last Year’s EPS
-3.14Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 17, 2021
|% Change Since: 83.97%
|Next Earnings Date:Mar 25, 2021
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth, improved gross margins, and strategic expansions. However, increased net loss and cash burn, along with decreased VIP enrollment revenue, are notable challenges. The sentiment is balanced with positive growth countered by financial losses.Company Guidance
During the Vivos Therapeutics Q3 2024 earnings call, the company reported a 17% increase in total revenue, reaching $3.9 million compared to $3.3 million in Q3 2023. Product revenue saw a significant 34% rise due to increased sales of Vivos appliances and a substantial 83% reduction in discounts. Gross profit improved by 34% to $2.3 million, with gross margins climbing to 60% from 53% in the prior year. Sales and marketing expenses dropped by 46% to $300,000, and general and administrative expenses fell 20% over the nine months ending September 30, 2024. Despite these positive metrics, net loss for the quarter increased by 25% to $2.6 million, primarily due to changes in the fair value of a warrant liability. Vivos also highlighted their strategic shift towards an alliance-based sales model with sleep centers, aiming to enhance patient access and reduce reliance on VIP enrollments.Revenue Growth
Third quarter 2024 total revenue was $3.9 million, a 17% increase from the same quarter in 2023, driven by increased product and service revenue.
Improved Gross Margin
Gross margin for the third quarter of 2024 improved to 60% from 53% in the third quarter of 2023.
Cost Reduction
Sales and marketing expenses decreased by 46% in the third quarter of 2024 compared to the same period last year, contributing to a reduction in operating loss.
Strategic Partnerships
Initiated a strategic marketing and distribution alliance with Rebis Health, expanding operations to new locations in Colorado.
FDA Clearances
Received FDA clearance for treating moderate to severe OSA in children ages 6 to 17, expanding treatment opportunities.
---
VVOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VVOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $3.12 | $2.84 | -8.97% |
| Aug 14, 2024 | $2.37 | $2.25 | -5.06% |
| May 14, 2024 | $2.49 | $2.18 | -12.45% |
| Mar 28, 2024 | $4.83 | $3.37 | -30.23% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vivos Therapeutics (VVOS) report earnings?
Vivos Therapeutics (VVOS) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Vivos Therapeutics (VVOS) earnings time?
Vivos Therapeutics (VVOS) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VVOS EPS forecast?
VVOS EPS forecast for the fiscal quarter 2024 (Q4) is -0.4.
---